aap: 30% Nine-Month Sales Growth to EUR 24.2 million

aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment and active in medical biomaterials, fracture healing and joint replacement, boosted - according to preliminary figures – sales revenues by 36% to EUR 8,0 million (previous year: EUR 5.9 million) in the third quarter of the fiscal year 2008. Sales growth in the first nine months was 30% to EUR 24.2 million (previous year: EUR 18.6 million).

Sales growth was achieved by the above-average development of the trauma & orthopaedics segment of aap throughout the first nine months of 2008 (+57% to EUR 9.4 million) and the successful development of the aap bio implants group in the third quarter, where revenues exceeded the third quarter revenues of 2007 by 46%.

For 2008 aap anticipates an organic sales growth of more than 20%, with above-average impact on the company’s operating result and net income. The publication of the full report on aap Implantate AG’s third quarter of 2008 is scheduled for November 7, 2008.